ReviewiScience2025
Polo-like kinase 4: A molecular linchpin in cancer and its management.
Review in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stress adaptation pathways and HA-CD44 signaling maintain the survival of pancreatic cancer cells with centrosome amplification.Cell communication and signaling : CCS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Genomic instability and cell cycle dysregulation are considered hallmarks of cancer. Polo-like kinase 4 (PLK4), a member of the PLK family, is essential for faithful centriole duplication, which, when dysregulated, contributes to genomic instability, cell cycle disruption, and cancer development. PLK4 overexpression has been correlated with progression, metastasis, and poor patient survival in multiple cancers. However, the in-depth understanding of signaling pathways and the regulation of PLK4 in cancers continues to evolve. Similarly, the strategy of PLK4 inhibition for cancer management is currently being actively investigated. This review discusses the existing knowledge on the role and function of PLK4 and its relationship with genomic instability and cancer. Additionally, we have summarized studies showing the association of PLK4 with multiple cancers and how its modulation affects cancer progression. Further, we have discussed PLK4 inhibitors and molecular pathways that could be associated with PLK4 and can open new avenues in cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.